A Closer Look at Emerging Delivery Systems That Can Improve the Treatment of Age-related Macular Degeneration and Diabetic Macular Edema

Author(s)/Faculty: Peter A. Campochiaro, MD; Arshad M. Khanani, MD, MA; Carl D. Regillo, MD, FACS
Release Date: 8/13/2021Expiration Date: 8/12/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 1.25
Content Type: VideoProvider:
Visual acuity outcomes observed with intravitreal anti-vascular endothelial growth factor (VEGF) therapy for the management of patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are often overshadowed by treatment burden and loss of patient adherence to dosing schedules. Clinical evaluation of sustained delivery devices and gene therapy is ongoing. These emerging options have the potential to extend the intervals between treatment dosing but require unique surgical approaches for optimal safety and efficacy outcomes. In this CME activity, experts in the field evaluate surgical delivery systems that may extend the intervals between treatment dosing, review unique surgical approaches for each system, and provide firsthand experience for the safe integration of surgical delivery systems into clinical practice.